Literature DB >> 9875313

Human papillomavirus-induced carcinogenesis with p53 deficiency in mouse: novel lymphomagenesis in HPV16E6E7 transgenic mice mimicking p53 defect.

Q Li1, N Yoshioka, M Yutsudo, S Inafuku, K Aozasa, Y Kitamura, S Aizawa, Y Nishimune, A Hakura, G Kondoh.   

Abstract

To investigate the transforming activity of human papillomavirus (HPV) E6 and E7 genes in vivo, we previously established transgenic mouse lines containing HPV16E6E7, in which male mice develop a Leydig cell tumors with a very high incidence. Because HPV-induced carcinogenesis is highly related to p53, we changed the dose of p53 gene in the transgenic lines by the mice crossing with p53-disrupted mice. The transgenic mice with homozygous wild-type p53 alleles developed only the testicular tumor, whereas novel T cell lymphomagenesis occurred in the heterozygous p53-disrupted E6E7 (p53+/-E6E7) transgenic mice. In this tumor and even in the normal spleen, the absence of p53 protein was observed, whereas the p53 mRNA was expressed with a normal size, suggesting the degradation of p53 protein in these tissues. These results suggest that HPV16E6 could stimulate p53 protein degradation in mouse cells and induced the lymphomagenesis in a manner indistinguishable from p53 deficiency.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9875313     DOI: 10.1006/viro.1998.9417

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  2 in total

1.  Analysis of p53 inactivation in a human T-cell leukemia virus type 1 Tax transgenic mouse model.

Authors:  T Portis; W J Grossman; J C Harding; J L Hess; L Ratner
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

2.  Sister chromatid telomere fusions, but not NHEJ-mediated inter-chromosomal telomere fusions, occur independently of DNA ligases 3 and 4.

Authors:  Kate Liddiard; Brian Ruis; Taylor Takasugi; Adam Harvey; Kevin E Ashelford; Eric A Hendrickson; Duncan M Baird
Journal:  Genome Res       Date:  2016-03-03       Impact factor: 9.043

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.